Institutional members access full text with Ovid®

Share this article on:

Type 2 Diabetes: Treat to Target

Funnell, Martha M. MS, RN, CDE; Kruger, Davida F. MSN, APRN, BC-ADM

Features: CE

Traditionally, practitioners have reserved insulin therapy for patients with type 2 diabetes until diet, exercise, and treatment with oral agents have failed to maintain glycemic control. Increasing evidence, however, supports advancing insulin therapy earlier in treating diabetes, not only to normalize glycemic control and emulate normal physiologic insulin secretion, but also to delay or prevent disease-associated comorbidity.


Martha M. Funnell is Director for Administration at the Michigan Diabetes Research and Training Center, Ann Arbor, Mich. Davida F. Kruger is a Certified Nurse Practitioner at Henry Ford Health System, Division of Endocrinology & Bone and Mineral Metabolism, Detroit, Mich.

© 2004 Lippincott Williams & Wilkins, Inc.